Click Here to return To Results

 

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis NEJM 365:1293-1303, OConnor, P.,et al, 2011 See this aricle in Pubmed Article Abstract Teriflunomide significantly reduced relapse rates, disability progression (at the higher dose), and MRI evidence of disease activity, as compared with placebo.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction efficacy immunomodulation immunosuppressive agents MRI MRI,abnormal MRI,lesion burden multiple sclerosis multiple sclerosis,disability status scale multiple sclerosis,relapsing multiple sclerosis,treatment of safety teriflunomide treatment of neurologic disorder

Click Here to return To Results